SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)

NCT00798213 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

29

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia, Myeloid, Acute
Lymphoblastic Leukemia, Acute

Interventions

DRUG: SCH 727965
DRUG: Gemtuzumab ozogamicin

Sponsor

Merck Sharp & Dohme LLC